0.75 USD
▼-0.00-0.39%
盘后 0.63 0.00%
2026-09-16
市值
$29.15M
市盈率
—
EPS
-0.16
股息率
—
52 周区间
0.57 – 2.44
成交量
19.85K
Beta
0.06
目标价
—
52W 低 0.5752W 高 2.44
价格走势
公司简介
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropen...